Lenka Hošková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lenka Hošková has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Josef Kautzner
Klinika kardiologie Institut klinické a experimentální medicíny Praha Česká republika
11 shared publicationsIvan Málek
Heart Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
8 shared publicationsJanka Franeková
Pracoviště laboratorních metod Institut klinické a experimentální medicíny a 3. lékařská fakulta Univerzity Karlovy Praha, Česká republika
6 shared publications- Peter Sečník
SK-Lab s.r.o., Partizanska 15, SK-984 01, Lucenec, Slovakia
6 shared publications J. Pirk
Cardiovascular Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
5 shared publications- Vojtech Melenovsky
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
5 shared publications
Latest Publications
- 19 October 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14626
Establishing a nationwide pediatric heart transplantation program with mid‐term results comparable to worldwide data – The Czech experience
Background: Heart transplantation (HTx) is an established therapeutic option for children with end‐stage heart failure. Comprehensive pediatric nationwide HTx program was introduced in 2014 in the Czech Republic. The aim of this study was to evaluate its mid‐term characteristics and outcomes and to compare them with international data.Methods: Retrospective observational study, including all patients who underwent HTx from June 2014 till December 2022. Data from the institutional database were used for descriptive statistics and survival analyses.Results: A total of 30 HTx were performed in 29 patients with congenital heart disease (CHD, N = 15, single ventricular physiology in 10 patients) and cardiomyopathy (CMP, N = 14). Ten patients were bridged to HTx by durable left ventricular assist devices (LVADs) for a mean duration of 104 (SD 89) days. There was one early and one late death during median follow‐up of 3.3 (IQR 1.3–6.1) years. Survival probability at 5 years after HTx was 93%. Two patients underwent re‐transplantation (one of them in an adult center). Significant rejection‐free survival at 1, 3, and 6 years after HTx was 76%, 63%, and 63%, respectively.Conclusions: The introduced pediatric HTx program reflects the complexity of the treated population, with half of the patients having complex CHD and one‐third being bridged to HTx by LVADs. Mid‐term results are comparable to worldwide data. The data confirm the possibility of establishing a successful nationwide pediatric HTx program in a relatively small population country with well‐developed pediatric cardiovascular care and other transplantation programs.
- 19 October 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14626
Establishing a nationwide pediatric heart transplantation program with mid‐term results comparable to worldwide data – The Czech experience
Background: Heart transplantation (HTx) is an established therapeutic option for children with end‐stage heart failure. Comprehensive pediatric nationwide HTx program was introduced in 2014 in the Czech Republic. The aim of this study was to evaluate its mid‐term characteristics and outcomes and to compare them with international data.Methods: Retrospective observational study, including all patients who underwent HTx from June 2014 till December 2022. Data from the institutional database were used for descriptive statistics and survival analyses.Results: A total of 30 HTx were performed in 29 patients with congenital heart disease (CHD, N = 15, single ventricular physiology in 10 patients) and cardiomyopathy (CMP, N = 14). Ten patients were bridged to HTx by durable left ventricular assist devices (LVADs) for a mean duration of 104 (SD 89) days. There was one early and one late death during median follow‐up of 3.3 (IQR 1.3–6.1) years. Survival probability at 5 years after HTx was 93%. Two patients underwent re‐transplantation (one of them in an adult center). Significant rejection‐free survival at 1, 3, and 6 years after HTx was 76%, 63%, and 63%, respectively.Conclusions: The introduced pediatric HTx program reflects the complexity of the treated population, with half of the patients having complex CHD and one‐third being bridged to HTx by LVADs. Mid‐term results are comparable to worldwide data. The data confirm the possibility of establishing a successful nationwide pediatric HTx program in a relatively small population country with well‐developed pediatric cardiovascular care and other transplantation programs.
- Open Access
- 6 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8475
Kidney Response to Chemotherapy-Induced Heart Failure: mRNA Analysis in Normotensive and Ren-2 Transgenic Hypertensive Rats
The aim of the present study was to perform kidney messenger ribonucleic acid (mRNA) analysis in normotensive, Hannover Sprague–Dawley (HanSD) rats and hypertensive, Ren-2 renin transgenic rats (TGR) after doxorubicin-induced heart failure (HF) with specific focus on genes that are implicated in the pathophysiology of HF-associated cardiorenal syndrome. We found that in both strains renin and angiotensin-converting enzyme mRNA expressions were upregulated indicating that the vasoconstrictor axis of the renin–angiotensin system was activated. We found that pre-proendothelin-1, endothelin-converting enzyme type 1 and endothelin type A receptor mRNA expressions were upregulated in HanSD rats, but not in TGR, suggesting the activation of endothelin system in HanSD rats, but not in TGR. We found that mRNA expression of cytochrome P-450 subfamily 2C23 was downregulated in TGR and not in HanSD rats, suggesting the deficiency in the intrarenal cytochrome P450-dependent pathway of arachidonic acid metabolism in TGR. These results should be the basis for future studies evaluating the pathophysiology of cardiorenal syndrome secondary to chemotherapy-induced HF in order to potentially develop new therapeutic approaches.
- 6 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8475
Open AccessKidney Response to Chemotherapy-Induced Heart Failure: mRNA Analysis in Normotensive and Ren-2 Transgenic Hypertensive Rats
The aim of the present study was to perform kidney messenger ribonucleic acid (mRNA) analysis in normotensive, Hannover Sprague–Dawley (HanSD) rats and hypertensive, Ren-2 renin transgenic rats (TGR) after doxorubicin-induced heart failure (HF) with specific focus on genes that are implicated in the pathophysiology of HF-associated cardiorenal syndrome. We found that in both strains renin and angiotensin-converting enzyme mRNA expressions were upregulated indicating that the vasoconstrictor axis of the renin–angiotensin system was activated. We found that pre-proendothelin-1, endothelin-converting enzyme type 1 and endothelin type A receptor mRNA expressions were upregulated in HanSD rats, but not in TGR, suggesting the activation of endothelin system in HanSD rats, but not in TGR. We found that mRNA expression of cytochrome P-450 subfamily 2C23 was downregulated in TGR and not in HanSD rats, suggesting the deficiency in the intrarenal cytochrome P450-dependent pathway of arachidonic acid metabolism in TGR. These results should be the basis for future studies evaluating the pathophysiology of cardiorenal syndrome secondary to chemotherapy-induced HF in order to potentially develop new therapeutic approaches.
- Open Access
- 8 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9337
Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat
Doxorubicin’s (DOX) cardiotoxicity contributes to the development of chemotherapy-induced heart failure (HF) and new treatment strategies are in high demand. The aim of the present study was to characterize a DOX-induced model of HF in Ren-2 transgenic rats (TGR), those characterized by hypertension and hyperactivity of the renin-angiotensin-aldosterone system, and to compare the results with normotensive transgene-negative, Hannover Sprague-Dawley (HanSD) rats. DOX was administered for two weeks in a cumulative dose of 15 mg/kg. In HanSD rats DOX administration resulted in the development of an early phase of HF with the dominant symptom of bilateral cardiac atrophy demonstrable two weeks after the last DOX injection. In TGR, DOX caused substantial impairment of systolic function already at the end of the treatment, with further progression observed throughout the experiment. Additionally, two weeks after the termination of DOX treatment, TGR exhibited signs of HF characteristic for the transition stage between the compensated and decompensated phases of HF. In conclusion, we suggest that DOX-induced HF in TGR is a suitable model to study the pathophysiological aspects of chemotherapy-induced HF and to evaluate novel therapeutic strategies to combat this form of HF, which are urgently needed.
- 8 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9337
Open AccessDeleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat
Doxorubicin’s (DOX) cardiotoxicity contributes to the development of chemotherapy-induced heart failure (HF) and new treatment strategies are in high demand. The aim of the present study was to characterize a DOX-induced model of HF in Ren-2 transgenic rats (TGR), those characterized by hypertension and hyperactivity of the renin-angiotensin-aldosterone system, and to compare the results with normotensive transgene-negative, Hannover Sprague-Dawley (HanSD) rats. DOX was administered for two weeks in a cumulative dose of 15 mg/kg. In HanSD rats DOX administration resulted in the development of an early phase of HF with the dominant symptom of bilateral cardiac atrophy demonstrable two weeks after the last DOX injection. In TGR, DOX caused substantial impairment of systolic function already at the end of the treatment, with further progression observed throughout the experiment. Additionally, two weeks after the termination of DOX treatment, TGR exhibited signs of HF characteristic for the transition stage between the compensated and decompensated phases of HF. In conclusion, we suggest that DOX-induced HF in TGR is a suitable model to study the pathophysiological aspects of chemotherapy-induced HF and to evaluate novel therapeutic strategies to combat this form of HF, which are urgently needed.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2805Elevated PCSK9 levels may contribute to dyslipidemia early after cardiac trasplantation
Background: Dyslipidemia after heart transplantation (HTx) contributes to early intimal thickening and development of coronary allograft vasculopathy which is the main reason for late graft loss. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that regulates low density lipoprotein cholesterol (LDL-C) levels by affecting stability of LDL-C receptor, that is targetable by novel drug therapy.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2805Elevated PCSK9 levels may contribute to dyslipidemia early after cardiac trasplantation
Background: Dyslipidemia after heart transplantation (HTx) contributes to early intimal thickening and development of coronary allograft vasculopathy which is the main reason for late graft loss. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that regulates low density lipoprotein cholesterol (LDL-C) levels by affecting stability of LDL-C receptor, that is targetable by novel drug therapy.
- 1 June 2018
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 60 (3) , e209-e214
Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice
Metodika: Do sledování byla zařazena skupina 12 pacientů s chronickým systolickým srdečním selháním (jedenáct mužů, jedna žena). Celkem 41,7 % pacientů mělo srdeční selhání v důsledku ischemické choroby srdeční (ICHS). Průměrná funkční třída NYHA byla 2,7 a průměrná ejekční frakce levé komory činila 26,5 %. Pacienti byli převedeni z terapie ACEI/blokátoru receptoru pro angiotensin II (ARB) na S/V. Laboratorní vyšetření, Minnesotský dotazník kvality života a šestiminutový test chůzí byly provedeny před změnou medikace a po třech měsících. Výsledky: Převod z ACEI/ARB na S/V nebyl spojen se žádnou nepříznivou příhodou. Terapie S/V vedla po třech měsících k poklesu systolického i diastolického krevního tlaku (-14,8, resp.-9,6 mm Hg) a poklesu sérové koncentrace draslíku (-0,27 mmol/l, všechna p < 0,05). Nedošlo ke zhoršení renálních funkcí (koncentrace kreatininu-7,8 μmol/l, p = 0,12, odhadovaná glomerulární fi ltrace +0,08 ml/s/1,73 m 2 , p = 0,14). Nedošlo ke změně koncentrace natriuretického peptidu typu B (BNP, p = 0,18), ale zaznamenali jsme významný pokles N-terminálního fragmentu BNP (NT-proBNP) (medián 1 012 ng/l před konverzí, 559,4 ng/l za tři měsíce, p = 0,005). Rovněž jsme zaznamenali malý, ale signifi kantní pokles vysoce senzitivního troponinu T (hs-cTnT, medián před konverzí 14,76 ng/l, 12,63 ng/l za tři měsíce, p = 0,001). Došlo ke zlepšení kvality života pacientů (zlepšení v Minnesotském dotazníku kvality života o osm bodů, p = 0,006) a k prodloužení vzdálenosti v šestiminutovém testu chůzí (+55 metrů, p = 0,0007), což nebylo na vrub zvýšeného úsilí. Závěr: Konverze z ACEI/ARB na S/V se jeví u stabilních nemocných s chronickým systolickým srdečním selháním jako bezpečná a vede ke zlepšení tolerance námahy a kvality života.
- 1 June 2018
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 60 (3) , e209-e214
Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice
Metodika: Do sledování byla zařazena skupina 12 pacientů s chronickým systolickým srdečním selháním (jedenáct mužů, jedna žena). Celkem 41,7 % pacientů mělo srdeční selhání v důsledku ischemické choroby srdeční (ICHS). Průměrná funkční třída NYHA byla 2,7 a průměrná ejekční frakce levé komory činila 26,5 %. Pacienti byli převedeni z terapie ACEI/blokátoru receptoru pro angiotensin II (ARB) na S/V. Laboratorní vyšetření, Minnesotský dotazník kvality života a šestiminutový test chůzí byly provedeny před změnou medikace a po třech měsících. Výsledky: Převod z ACEI/ARB na S/V nebyl spojen se žádnou nepříznivou příhodou. Terapie S/V vedla po třech měsících k poklesu systolického i diastolického krevního tlaku (-14,8, resp.-9,6 mm Hg) a poklesu sérové koncentrace draslíku (-0,27 mmol/l, všechna p < 0,05). Nedošlo ke zhoršení renálních funkcí (koncentrace kreatininu-7,8 μmol/l, p = 0,12, odhadovaná glomerulární fi ltrace +0,08 ml/s/1,73 m 2 , p = 0,14). Nedošlo ke změně koncentrace natriuretického peptidu typu B (BNP, p = 0,18), ale zaznamenali jsme významný pokles N-terminálního fragmentu BNP (NT-proBNP) (medián 1 012 ng/l před konverzí, 559,4 ng/l za tři měsíce, p = 0,005). Rovněž jsme zaznamenali malý, ale signifi kantní pokles vysoce senzitivního troponinu T (hs-cTnT, medián před konverzí 14,76 ng/l, 12,63 ng/l za tři měsíce, p = 0,001). Došlo ke zlepšení kvality života pacientů (zlepšení v Minnesotském dotazníku kvality života o osm bodů, p = 0,006) a k prodloužení vzdálenosti v šestiminutovém testu chůzí (+55 metrů, p = 0,0007), což nebylo na vrub zvýšeného úsilí. Závěr: Konverze z ACEI/ARB na S/V se jeví u stabilních nemocných s chronickým systolickým srdečním selháním jako bezpečná a vede ke zlepšení tolerance námahy a kvality života.
- 1 April 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (4) , S353-S354
The Effect of Dual Renin-angiotensin System Blockade Compared to Conventional Antihypertensive Combination on Blood Pressure and Renal Function After Heart Transplantation: A Randomized Controlled Trial
- 1 April 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (4) , S353-S354
The Effect of Dual Renin-angiotensin System Blockade Compared to Conventional Antihypertensive Combination on Blood Pressure and Renal Function After Heart Transplantation: A Randomized Controlled Trial
- 16 April 2017
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 66 (2) , 167-180
Pathophysiological Mechanisms of Calcineurin Inhibitor-Induced Nephrotoxicity and Arterial Hypertension
Solid organ transplantation is an established treatment modality in patients with end-stage organ damage in cases where other therapeutic options fail. The long-term outcomes of solid organ transplant recipients have improved considerably since the introduction of the first calcineurin inhibitor (CNI) - cyclosporine. In 1984, the potent immunosuppressive properties of another CNI, tacrolimus, were discovered. The immunosuppressive effects of CNIs result from the inhibition of interleukin-2 synthesis and reduced proliferation of T cells due to calcineurin blockade. The considerable side effects that are associated with CNIs therapy include arterial hypertension and nephrotoxicity. The focus of this article was to review the available literature on the pathophysiological mechanisms of CNIs that induce chronic nephrotoxicity and arterial hypertension. CNIs lead to activation of the major vasoconstriction systems, such as the renin-angiotensin and endothelin systems, and increase sympathetic nerve activity. On the other hand, CNIs are known to inhibit NO synthesis and NO-mediated vasodilation and to increase free radical formation. Altogether, these processes cause endothelial dysfunction and contribute to the impairment of organ function. A better insight into the mechanisms underlying CNI nephrotoxicity could assist in developing more targeted therapies of arterial hypertension or preventing CNI nephrotoxicity in organ transplant recipients, including heart transplantation.
- 16 April 2017
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 66 (2) , 167-180
Pathophysiological Mechanisms of Calcineurin Inhibitor-Induced Nephrotoxicity and Arterial Hypertension
Solid organ transplantation is an established treatment modality in patients with end-stage organ damage in cases where other therapeutic options fail. The long-term outcomes of solid organ transplant recipients have improved considerably since the introduction of the first calcineurin inhibitor (CNI) - cyclosporine. In 1984, the potent immunosuppressive properties of another CNI, tacrolimus, were discovered. The immunosuppressive effects of CNIs result from the inhibition of interleukin-2 synthesis and reduced proliferation of T cells due to calcineurin blockade. The considerable side effects that are associated with CNIs therapy include arterial hypertension and nephrotoxicity. The focus of this article was to review the available literature on the pathophysiological mechanisms of CNIs that induce chronic nephrotoxicity and arterial hypertension. CNIs lead to activation of the major vasoconstriction systems, such as the renin-angiotensin and endothelin systems, and increase sympathetic nerve activity. On the other hand, CNIs are known to inhibit NO synthesis and NO-mediated vasodilation and to increase free radical formation. Altogether, these processes cause endothelial dysfunction and contribute to the impairment of organ function. A better insight into the mechanisms underlying CNI nephrotoxicity could assist in developing more targeted therapies of arterial hypertension or preventing CNI nephrotoxicity in organ transplant recipients, including heart transplantation.
- 1 March 2017
- Published by Elsevier in Transplant Immunology
- Vol. 41, 22-26
Free light chain and intact immunoglobulin abnormalities in heart transplant recipients: Two year follow-up timelines and clinical correlations
- 1 March 2017
- Published by Elsevier in Transplant Immunology
- Vol. 41, 22-26
Free light chain and intact immunoglobulin abnormalities in heart transplant recipients: Two year follow-up timelines and clinical correlations
- 9 December 2016
- Published by Wiley in Clinical Transplantation
- Vol. 31 (1)
Serial measurement of presepsin, procalcitonin, and C‐reactive protein in the early postoperative period and the response to antithymocyte globulin administration after heart transplantation
Differentiation between systemic inflammatory response syndrome and sepsis in surgical patients is of crucial significance. Procalcitonin (PCT) and C‐reactive protein (CRP) are widely used biomarkers, but PCT becomes compromised after antithymocyte globulin (ATG) administration, and CRP exhibits limited specificity. Presepsin has been suggested as an alternative biomarker of sepsis. This study aimed to demonstrate the role of presepsin in patients after heart transplantation (HTx). Plasma presepsin, PCT, and CRP were measured in 107 patients serially for up to 10 days following HTx. Time responses of biomarkers were evaluated for both noninfected (n=91) and infected (n=16) patients. Areas under the concentration curve differed in the two groups of patients for presepsin (P<.001), PCT (P<.005), and CRP (P<.001). The effect of time and infection was significant for all three biomarkers (P<.05 all). In contrast to PCT, presepsin was not influenced by ATG administration. More than 25% of noninfected patients had PCT above 42 μg/L on the first day, and the peak concentration of CRP in infected patients was reached on the third post‐transplant day (median 135 mg/L). Presepsin seems to be as valuable a biomarker as PCT or CRP in the evaluation of infectious complications in patients after HTx.
- 9 December 2016
- Published by Wiley in Clinical Transplantation
- Vol. 31 (1)
Serial measurement of presepsin, procalcitonin, and C‐reactive protein in the early postoperative period and the response to antithymocyte globulin administration after heart transplantation
Differentiation between systemic inflammatory response syndrome and sepsis in surgical patients is of crucial significance. Procalcitonin (PCT) and C‐reactive protein (CRP) are widely used biomarkers, but PCT becomes compromised after antithymocyte globulin (ATG) administration, and CRP exhibits limited specificity. Presepsin has been suggested as an alternative biomarker of sepsis. This study aimed to demonstrate the role of presepsin in patients after heart transplantation (HTx). Plasma presepsin, PCT, and CRP were measured in 107 patients serially for up to 10 days following HTx. Time responses of biomarkers were evaluated for both noninfected (n=91) and infected (n=16) patients. Areas under the concentration curve differed in the two groups of patients for presepsin (P<.001), PCT (P<.005), and CRP (P<.001). The effect of time and infection was significant for all three biomarkers (P<.05 all). In contrast to PCT, presepsin was not influenced by ATG administration. More than 25% of noninfected patients had PCT above 42 μg/L on the first day, and the peak concentration of CRP in infected patients was reached on the third post‐transplant day (median 135 mg/L). Presepsin seems to be as valuable a biomarker as PCT or CRP in the evaluation of infectious complications in patients after HTx.